AIM ImmunoTech
AIM

$0.36

2.38%

Market Cap: 20.8M

About: AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Employees: 28

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

6% more capital invested

Capital invested by funds: $1.83M [Q4 2023] → $1.93M (+$101K) [Q1 2024]

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

0.12% less ownership

Funds ownership: 8.5% [Q4 2023] → 8.38% (-0.12%) [Q1 2024]

13% less funds holding

Funds holding: 38 [Q4 2023] → 33 (-5) [Q1 2024]

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for AIM.

See Analyst Rankings

Financial journalist opinion

AIM Announces New Positive Data on Ampligen's Anti-Tumor Potential When Used as Part of a Combination Therapy

OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company's drug Ampligen as part of a combinational therapy in the treatment of melanoma, showing that combination dendritic cell-based vaccines including anti-PD-L1 checkpoint inhibitors and Ampligen-containing chemokine modulation helped slow tumor cell growth and improved survival in a mouse model.

AIM Announces New Positive Data on Ampligen's Anti-Tumor Potential When Used as Part of a Combination Therapy

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

OCALA, Fla., July 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provided an update on the Phase 1b/2 “DURIPANC” study of Ampligen and AstraZeneca's Imfinzi as a combination therapy for late-stage pancreatic cancer. The Company also provided a business update, including that as a result of recent financings, AIM recently had stockholders' equity of $6.9 million.

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K.

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ET Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ET

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of common stock in a registered direct offering at a purchase price of $0.363 per share. In a concurrent private placement, the Company also agreed to issue unregistered Class A warrants to purchase up to an aggregate of 5,640,958 shares of common stock and, unregistered Class B warrants to purchase up to an aggregate of 5,640,958 shares of common stock. The Class A and Class B warrants will each have an exercise price of $0.363, will be exercisable six months from the date of issuance and, in the case of the Class A warrants, will expire on the eighteen-month anniversary from the initial exercise date, and in the case of the Class B warrants, will expire on the five-year anniversary from the initial exercise date.

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences

OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor conferences.

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences

AIM ImmunoTech Inc. (AIM) Q1 2024 Earnings Call Transcript

AIM ImmunoTech Inc. (NYSE:AIM ) Q1 2024 Earnings Conference Call May 16, 2024 8:30 AM ET Company Participants Thomas Equels - CEO Christopher McAleer - Scientific Officer Conference Call Participants James Molloy - Alliance Global Partners Ed Woo - Ascendiant Capital Markets Operator Hello, and welcome to the AIM ImmunoTech First Quarter 2024 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

AIM ImmunoTech Inc. (AIM) Q1 2024 Earnings Call Transcript

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

Aimia Inc. (AIMFF) Q1 2024 Earnings Call Transcript

Aimia Inc. (OTCPK:AIMFF) Q1 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Joe Racanelli - VP, IR and Communications Tom Finke - Executive Chairman Steve Leonard - Chief Financial Officer Conference Call Participants Surinder Thind - Jefferies Brian Morrison - TD Cowen Operator Good morning, ladies and gentlemen. And welcome to the Aimia Inc. First Quarter 2024 Results Conference Call.

Aimia Inc. (AIMFF) Q1 2024 Earnings Call Transcript

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company's Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET.

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

See News Rankings